NASDAQ:ALBO - Albireo Pharma Stock Price, Forecast & News

Albireo Pharma trades on the NASDAQ under the ticker symbol "ALBO."

Albireo Pharma Inc (NASDAQ:ALBO) issued its quarterly earnings data on Wednesday, November, 6th. The biopharmaceutical company reported ($1.73) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($1.55) by $0.18. The biopharmaceutical company had revenue of $1.39 million for the quarter, compared to the consensus estimate of $1.38 million. Albireo Pharma had a negative return on equity of 62.69% and a negative net margin of 1,881.86%. View Albireo Pharma's Earnings History.

Albireo Pharma is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Albireo Pharma.

4 analysts have issued 12 month price objectives for Albireo Pharma's shares. Their forecasts range from $39.00 to $69.00. On average, they anticipate Albireo Pharma's share price to reach $56.67 in the next twelve months. This suggests a possible upside of 143.8% from the stock's current price. View Analyst Price Targets for Albireo Pharma.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Albireo Pharma in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Albireo Pharma.

News stories about ALBO stock have trended somewhat negative on Tuesday, InfoTrie reports. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Albireo Pharma earned a news impact score of -1.4 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Albireo Pharma.

Albireo Pharma saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 791,600 shares, an increase of 6.0% from the December 15th total of 746,900 shares. Based on an average trading volume of 72,500 shares, the days-to-cover ratio is currently 10.9 days. Currently, 7.8% of the shares of the stock are sold short. View Albireo Pharma's Current Options Chain.

Some companies that are related to Albireo Pharma include Madrigal Pharmaceuticals (MDGL), ZEALAND PHARMA/S (ZEAL), Myovant Sciences (MYOV), Athenex (ATNX), Endonovo Therapeutics (ENDV), Rocket Pharmaceuticals (RCKT), Enanta Pharmaceuticals (ENTA), Portola Pharmaceuticals (PTLA), Opko Health (OPK), Phibro Animal Health (PAHC), Dermira (DERM), NextCure (NXTC), Karyopharm Therapeutics (KPTI), Revance Therapeutics (RVNC) and XBiotech (XBIT).

Based on aggregate information from My MarketBeat watchlists, some companies that other Albireo Pharma investors own include Energy Transfer LP Unit (ET), Heat Biologics (HTBX), CBL & Associates Properties (CBL), GW Pharmaceuticals PLC- (GWPH), Martin Midstream Partners (MMLP), Cornerstone Total Return Fund (CRF), Palatin Technologies (PTN), Exelixis (EXEL), Viking Therapeutics (VKTX) and SandRidge Permian Trust (PER).

Albireo Pharma's stock is owned by many different of retail and institutional investors. Top institutional investors include Chicago Capital LLC (1.38%), California Public Employees Retirement System (0.14%) and Alpine Global Management LLC (0.10%). Company insiders that own Albireo Pharma stock include Jan Mattsson, Patrick Taylor Horn, Phase4 Partners Ltd, Ronald Harold Wilfred Cooper and Simon NR Harford. View Institutional Ownership Trends for Albireo Pharma.

ALBO stock was sold by a variety of institutional investors in the last quarter, including Chicago Capital LLC. Company insiders that have sold Albireo Pharma company stock in the last year include Patrick Taylor Horn and Simon NR Harford. View Insider Buying and Selling for Albireo Pharma.

ALBO stock was purchased by a variety of institutional investors in the last quarter, including California Public Employees Retirement System and Alpine Global Management LLC. View Insider Buying and Selling for Albireo Pharma.

Shares of ALBO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ALBO stock can currently be purchased for approximately $23.24.

Albireo Pharma has a market capitalization of $294.92 million and generates $12.74 million in revenue each year. The biopharmaceutical company earns $-46,110,000.00 in net income (profit) each year or ($3.94) on an earnings per share basis. Albireo Pharma employs 39 workers across the globe.View Additional Information About Albireo Pharma.

The official website for Albireo Pharma is http://www.albireopharma.com/.

Albireo Pharma's mailing address is 10 POST OFFICE SQUARE SUITE 502 SOUTH, BOSTON MA, 02109. The biopharmaceutical company can be reached via phone at 857-254-5555 or via email at [email protected]